Why this matters for India: Generic entry could unlock a 5,000+ crore opportunity over the next 1215 months Prices may drop 3050% initially, and potentially 7075% over time #GLP-1 adoption in diabetes care is expected to rise sharply, adding 0.51% to IPM growth in FY27 Competition is intensifying, with 1015 players vying for share across India, regulated, and emerging markets Novo Nordisk has already launched Ozempic in India (Dec 2025), setting the stage for one of the most closely watched generic transitions in recent pharma history
Sources include oats, chia seeds, flaxseeds, apples, citrus fruits, beans, and psyllium husk
One survey found that over 50% of consumers see these prescriptions as 'very effective' for managing their weight
When glutathione levels drop, which can happen due to age, chronic illness, or high exposure to toxins, many men experience a range of undesirable symptoms, from fatigue to decreased cognitive performance
with Vitastir